ARTICLE | Company News
Calypso, EA Pharma deal
April 7, 2017 4:22 AM UTC
Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001. The companies will collaborate to develop the human mAb targeting matrix metalloproteinase 9 (MMP9) to treat inflammatory bowel disease (IBD). ...
BCIQ Target Profiles